Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neurana Pharmaceuticals

Request full access

Privately held clinical stage san diego based specialty pharmaceutical company

San Diego, United StatesFounded 2013Biotech & Life Sciences

About Neurana Pharmaceuticals

Neurana Pharmaceuticals, Inc. was a privately held, clinical-stage biotechnology company founded in 2013 and based in San Diego. The company focused on developing treatments for neuromuscular conditions, particularly acute, painful muscle spasms. Neurana's business model centered on the clinical development of a lead drug candidate with the goal of commercialization in North America.

The company's primary focus was its lead compound, tolperisone, a centrally acting skeletal muscle relaxant. This non-opioid treatment was being developed as a novel solution for patients with muscle spasms, aiming to provide pain relief without the common side effects of sedation, drowsiness, or cognitive impairment associated with other muscle relaxants on the market. Tolperisone acts by blocking voltage-gated sodium and calcium channels. The drug is already approved and widely used for similar indications in Europe and Asia. Neurana secured an exclusive license from Sanochemia AG to develop and commercialize a patented, purer composition of tolperisone that meets U.S. regulatory guidelines.

Neurana's journey involved significant fundraising and clinical trials. The company raised a total of $63.8 million over two rounds, including a substantial $60 million Series A financing in May 2018. This round was led by Sofinnova Investments and included other notable investors like New Leaf Venture Partners, Longitude Capital, and H.I.G. BioHealth Partners. The funds were intended to advance tolperisone through the clinical trial process. The company successfully completed a Phase 2 study which showed promising results for pain relief with sleepiness levels similar to a placebo. However, in March 2022, Neurana announced that its Phase 3 clinical study, RESUME-1, failed to meet its primary and key secondary endpoints for efficacy in relieving muscle spasm pain compared to a placebo. Following this outcome, the company's board decided to halt spending, reduce headcount, and explore strategic alternatives, including a potential dissolution of the company.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing May 2018 $60M $240M New Leaf Venture Partners · Longitude Capital · MagnaSci Ventures · Sofinnova Investments —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Neurana Pharmaceuticals website traffic

Latest recorded traffic for Neurana Pharmaceuticals is 250 monthly website visits, up 25% over the last three months. Neurana Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits250 3-month web change+25% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Neurana Pharmaceuticals in the San Diego ecosystem

Live from Dealroom

The Neurana Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Sofinnova Investments
  • New Leaf Venture Partners
  • Longitude Capital
  • MagnaSci Ventures
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neurana Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neurana Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.